cancer Cancer Discovery Cancer screening

A study suggests that epigenetic treatments could trigger the development of aggressive tumours

Cancer develops as a result of the accumulation of mutations in our cells. These mutations are not distributed evenly in our chromosomes, so some regions hold more than others. A study headed by the Institute for Research in Biomedicine (IRB Barcelona) and published in the journal Nature Cell Biologyexamined whether the opening of chromatin (a complex formed by DNA bound to proteins) is the factor that determines the accumulation of more
cancer

Scientific panel advises there is evidence for an association between both heart and brain cancers and cell phone radiation in large-scale animal study.

Scientists concluded there is “clear evidence” linking cell phone radiation to the development of cancers in rats. The U.S. government invited an expert panel to make a majority-rules declaration in response to the $25 million U.S. government National Toxicology Program (NTP) study of cell phone radiation in animals. After a three-day review of the study data, they voted to strengthen the conclusions that cell phone radiation caused health effects in
cancer Cancer Discovery

Researchers quantify breast cancer risk based on rare variants and background risk

Rare variants combined with background genetic risk factors may account for many unexplained cases of familial breast cancer, and knowing the specific genes involved could inform choice of prevention and treatment strategies, according to findings presented in a plenary session at the American Society of Human Genetics (ASHG) 2017 Annual Meeting in Orlando, Fla. Researchers Na Li, MD, who presented the work; Ian Campbell, PhD, lead investigator; and their colleagues
Cancer Discovery

A blood test can predict early lung cancer prognosis

Cancer cells obtained from a blood test may be able to predict how early-stage lung cancer patients will fare, a team from the University of Michigan has shown. This information could be used to determine which patients are most likely to benefit from additional therapies to head off the spread of the cancer to other areas of the body. With a new single cell analysis service in U-M's Comprehensive Cancer
cancer

New Biotechnology Partnership Formed to Develop Liver Cancer Chemotherapeutic

Q BioMed, Inc., a New York City-based biomedical acceleration and development company has entered into an agreement with the Oklahoma Medical Research Foundation (OMRF) and the Rajiv Gandhi Centre for Biotechnology (RGCB) to develop a chemotherapeutic technology to treat liver cancer. The technology will utilize “uttroside B” and the compound’s derivatives as a chemotherapeutic agent against hepatocellular carcinoma. The preclinical efficacy of uttroside B, a potent saponin, against liver cancer
Biotechnology cancer

Enzyme Could Protect Against Type of Colorectal Cancer By Suppressing Tumors, Study Finds

An enzyme that plays an active role in inflammation could be a natural way to suppress tumors and ulcers in the colon that are found in colitis associated cancer (CAC), a type of colorectal cancer that is driven by chronic inflammation, according to a new study. Researchers at Georgia State University and Stony Brook University have identified the tumor suppressor role of matrix-metalloproteinase (MMP9), which belongs to a family of
cancer Cancer Discovery

Researchers inhibit tumor growth in new subtype of lung cancer

Lung cancer is the most common cause of cancer deaths, accounting for about a third of all tumor-related deaths. Adenocarcinomas, a non-small cell lung cancer (NSCLC), account for about 40 percent of cancer diagnoses, but few treatments are available for the disease. A team of investigators led by Elena Levantini, PhD, a research associate in Hematology-Oncology at Beth Israel Deaconess Medical Center (BIDMC), instructor of medicine at Harvard Medical School
Biotechnology cancer Clinical Trials

Cancer Immunotherapies take Center Stage

[embed]https://vimeo.com/151833021[/embed] The newly created task force on cancer, in what Vice President Joe Biden has called a “moon shot” to cure the disease, is to put the US on a path to achieve in just five years research and treatment that otherwise might take a decades or more.  Although the memorandum does not commit the government to major new spending, the task force's role will be to focus on making
Biotechnology cancer Clinical Trials

Many Targeted Cancer Therapies Suppress T Cell Immune Responses

In many cases, targeted therapies for cancer are preferred as treatments over chemotherapy and surgery because they attack and kill cancer cells with specific tumor-promoting mutations while sparing healthy, normal cells that do not express these mutations. In clinical trials, a heavy emphasis on the effects of targeted therapies on tumor cells has been explored, but the effects they have on the immune system have not been thoroughly investigated. However,